Watch List News:: Broadcom Inc., (NASDAQ: AVGO)

Broadcom Inc., belongs to Technology sector and Semiconductor – Broad Line industry. The company’s Market capitalization is $105.78B with the …

EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to as the EPS growth rate. Growth in EPS is an important measure of administration performance because it shows how much money the company is making for it’s investors or shareholders, not only because of changes in profit, but also after all the effects of issuance of new shares (this is especially important when the growth comes as a result of acquisition).

Broadcom Inc., belongs to Technology sector and Semiconductor – Broad Line industry. The company’s Market capitalization is $105.78B with the total Outstanding Shares of 405.56M. On 18-01-2019 (Friday),AVGO stock construct a change of 2.15% (Gain , ) in a total of its share price and finished its trading at 260.82.

Broadcom Inc. institutional ownership is held at 88.8% while insider ownership was 0.2%. As of now, AVGO has a P/S, P/E and P/B values of 5.07, 22.9 and 4.03 respectively. Its P/Cash is valued at 0.

The stock has seen its SMA50 which is now 8.51%. In looking the SMA 200 we see that the stock has seen a 10.58%.The Company’s net profit margin for the 12 months at 58.8%. Comparatively, the gazes have a Gross margin 51.6%.

Profitability ratios:

Looking into the profitability ratios of AVGO stock, an investor will find its ROE, ROA, ROI standing at 43.8%, 23.4% and 13.2%, respectively.

Earnings per Share Details of Broadcom Inc.:

The EPS of AVGO is strolling at 11.39, measuring its EPS growth this year at 187.6%. As a result, the company has an EPS growth of 14.68% for the approaching year.

Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

We can’t have enough maintenance the once will always reflect the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to continue to take effect as a result.

Analyst’s mean target price for the company is $291.67 while analysts mean suggestion is 2.

A beta factor is used to measure the volatility of the stock. The stock remained 2.83% volatile for the week and 3.63% for the month.

Historical Performance In The News:

Taking a look at the performance of Broadcom Inc. stock, an investor will come to know that the weekly performance for this stock is valued at 4.09%, resulting in a performance for the month at 4.47%.

Therefore, the stated figure displays a quarterly performance of 9.97%, bringing six-month performance to 23.98% and year to date performance of 2.57%.As of now, Broadcom Inc. has a P/S, P/E and P/B values of 5.07, 22.9 and 4.03 respectively. Its P/Cash is valued at 0.

Related Posts:

  • No Related Posts

$0.04 EPS Expected for BioLife Solutions Inc (BLFS) This Quarter

Acadian Asset Management LLC boosted its holdings in shares of BioLife Solutions by 39.0% during the 3rd quarter. Acadian Asset Management LLC …

BioLife Solutions logoEquities analysts predict that BioLife Solutions Inc (NASDAQ:BLFS) will announce earnings of $0.04 per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for BioLife Solutions’ earnings, with the lowest EPS estimate coming in at $0.04 and the highest estimate coming in at $0.05. BioLife Solutions posted earnings of ($0.05) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 180%. The firm is expected to issue its next quarterly earnings report on Thursday, March 14th.

According to Zacks, analysts expect that BioLife Solutions will report full year earnings of $0.15 per share for the current fiscal year, with EPS estimates ranging from $0.14 to $0.16. For the next year, analysts anticipate that the business will post earnings of $0.26 per share, with EPS estimates ranging from $0.23 to $0.32. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, November 8th. The medical equipment provider reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.01. The business had revenue of $5.29 million during the quarter, compared to analyst estimates of $5.19 million. BioLife Solutions had a net margin of 10.42% and a return on equity of 8.63%.

A number of equities research analysts have weighed in on the stock. ValuEngine lowered shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 27th. B. Riley set a $22.00 target price on shares of BioLife Solutions and gave the company a “buy” rating in a research note on Wednesday, October 3rd. Finally, Janney Montgomery Scott upgraded shares of BioLife Solutions to a “buy” rating and set a $5.00 target price for the company in a research note on Thursday, December 20th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.75.

In other BioLife Solutions news, CEO Michael Rice sold 14,781 shares of the stock in a transaction on Thursday, December 13th. The stock was sold at an average price of $11.44, for a total value of $169,094.64. Following the completion of the sale, the chief executive officer now owns 154,298 shares in the company, valued at approximately $1,765,169.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Andrew G. Hinson sold 4,000 shares of the stock in a transaction on Thursday, December 13th. The stock was sold at an average price of $12.05, for a total value of $48,200.00. Following the completion of the sale, the director now owns 45,747 shares of the company’s stock, valued at approximately $551,251.35. The disclosure for this sale can be found here. Insiders sold a total of 56,562 shares of company stock valued at $664,696 over the last 90 days. 38.50% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. OppenheimerFunds Inc. purchased a new stake in BioLife Solutions in the 2nd quarter worth $130,000. Citadel Advisors LLC boosted its holdings in shares of BioLife Solutions by 53.8% during the 2nd quarter. Citadel Advisors LLC now owns 16,989 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 5,946 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of BioLife Solutions by 644.2% during the 2nd quarter. Renaissance Technologies LLC now owns 206,900 shares of the medical equipment provider’s stock valued at $2,361,000 after purchasing an additional 179,100 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of BioLife Solutions by 39.0% during the 3rd quarter. Acadian Asset Management LLC now owns 69,361 shares of the medical equipment provider’s stock valued at $1,213,000 after purchasing an additional 19,456 shares during the last quarter. Finally, Casdin Capital LLC bought a new position in shares of BioLife Solutions during the 2nd quarter valued at about $11,410,000. Institutional investors and hedge funds own 41.16% of the company’s stock.

BLFS traded down $0.44 during mid-day trading on Monday, reaching $12.20. 162,209 shares of the company traded hands, compared to its average volume of 132,100. The firm has a market cap of $225.70 million, a PE ratio of -58.10 and a beta of 1.46. BioLife Solutions has a 52-week low of $4.63 and a 52-week high of $26.35.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Featured Article: What are CEFs?

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioLife Solutions Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioLife Solutions and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Zacks: Brokerages Anticipate Carbon Black Inc (CBLK) Will Announce Earnings of -$0.24 Per Share

FNY Investment Advisers LLC purchased a new stake in Carbon Black in the 3rd quarter worth $105,000. Quantum Capital Management bought a …

Carbon Black logoBrokerages expect Carbon Black Inc (NASDAQ:CBLK) to report ($0.24) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Carbon Black’s earnings, with estimates ranging from ($0.25) to ($0.24). The firm is scheduled to announce its next earnings report on Thursday, January 24th.

According to Zacks, analysts expect that Carbon Black will report full year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.20) to ($1.18). For the next year, analysts expect that the firm will post earnings of ($0.70) per share, with EPS estimates ranging from ($0.74) to ($0.65). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Carbon Black.

Carbon Black (NASDAQ:CBLK) last posted its quarterly earnings data on Thursday, October 25th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.05. The company had revenue of $53.42 million during the quarter, compared to analysts’ expectations of $52.65 million.

Several research firms have recently commented on CBLK. Zacks Investment Research upgraded Carbon Black from a “sell” rating to a “hold” rating in a research note on Monday, December 17th. Morgan Stanley cut their price target on Carbon Black from $21.00 to $19.00 and set an “equal weight” rating for the company in a research note on Monday, October 29th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.83.

In other Carbon Black news, insider Michael Viscuso sold 50,000 shares of the stock in a transaction on Wednesday, January 16th. The stock was sold at an average price of $13.92, for a total value of $696,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Hedge funds have recently modified their holdings of the business. FNY Investment Advisers LLC purchased a new stake in Carbon Black in the 3rd quarter worth $105,000. Quantum Capital Management bought a new position in shares of Carbon Black during the 3rd quarter valued at about $291,000. Hershey Trust Co. bought a new position in shares of Carbon Black during the 4th quarter valued at about $294,000. Malaga Cove Capital LLC bought a new position in shares of Carbon Black during the 3rd quarter valued at about $310,000. Finally, Raymond James & Associates bought a new position in shares of Carbon Black during the 2nd quarter valued at about $499,000. Institutional investors and hedge funds own 26.11% of the company’s stock.

Shares of NASDAQ:CBLK traded down $0.06 during midday trading on Wednesday, hitting $14.30. The company had a trading volume of 863,958 shares, compared to its average volume of 608,175. Carbon Black has a 12-month low of $11.80 and a 12-month high of $35.00.

About Carbon Black

Carbon Black, Inc provides security solutions in the United States and internationally. Its security cloud platform captures, records, and analyzes unfiltered endpoint data. The company’s solutions enable customers to predict, prevent, detect, respond to and remediate cyber attacks before they cause a damaging incident or data breach.

Featured Article: What are CEFs?

Get a free copy of the Zacks research report on Carbon Black (CBLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Carbon Black (NASDAQ:CBLK)

Receive News & Ratings for Carbon Black Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Carbon Black and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Zacks: Brokerages Expect Microvision, Inc. (MVIS) to Post -$0.10 EPS

Millennium Management LLC purchased a new stake in shares of Microvision in the 2nd quarter valued at about $1,858,000. Uniplan Investment …

Microvision logoEquities analysts expect Microvision, Inc. (NASDAQ:MVIS) to post ($0.10) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Microvision’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.09). Microvision also reported earnings per share of ($0.10) during the same quarter last year. The company is scheduled to report its next quarterly earnings report on Thursday, February 28th.

According to Zacks, analysts expect that Microvision will report full year earnings of ($0.28) per share for the current year, with EPS estimates ranging from ($0.29) to ($0.28). For the next year, analysts anticipate that the company will post earnings of ($0.21) per share, with EPS estimates ranging from ($0.21) to ($0.20). Zacks’ EPS calculations are an average based on a survey of research firms that cover Microvision.

Several analysts have recently weighed in on MVIS shares. Zacks Investment Research raised Microvision from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Saturday, September 29th. ValuEngine raised Microvision from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Craig Hallum started coverage on Microvision in a report on Wednesday, December 19th. They issued a “buy” rating for the company. Finally, HC Wainwright set a $4.00 target price on Microvision and gave the company a “buy” rating in a report on Monday, December 31st.

Several institutional investors have recently bought and sold shares of MVIS. Millennium Management LLC purchased a new stake in shares of Microvision in the 2nd quarter valued at about $1,858,000. Uniplan Investment Counsel Inc. lifted its holdings in shares of Microvision by 84.0% in the 3rd quarter. Uniplan Investment Counsel Inc. now owns 2,188,958 shares of the electronics maker’s stock valued at $2,648,000 after purchasing an additional 999,414 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Microvision in the 2nd quarter valued at about $429,000. PVG Asset Management Corp purchased a new stake in shares of Microvision in the 2nd quarter valued at about $224,000. Finally, Jane Street Group LLC purchased a new stake in shares of Microvision in the 2nd quarter valued at about $136,000. 22.46% of the stock is owned by institutional investors and hedge funds.

NASDAQ MVIS remained flat at $$0.80 during trading on Wednesday. The company’s stock had a trading volume of 234,020 shares, compared to its average volume of 346,878. The stock has a market cap of $80.55 million, a P/E ratio of -2.44 and a beta of 0.46. Microvision has a 12 month low of $0.51 and a 12 month high of $1.80.

About Microvision

MicroVision, Inc develops PicoP scanning technology that provides high-resolution miniature projection, and three-dimensional sensing and image capture solutions in the United States. Its PicoP scanning technology comprises micro-electrical mechanical systems, laser diodes, opto-mechanics, and electronics.

Featured Story: Risk Tolerance

Get a free copy of the Zacks research report on Microvision (MVIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Microvision Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Microvision and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Brokerages Anticipate OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.18 Per Share

Finally, Millennium Management LLC increased its holdings in OncoSec Medical by 19.5% in the 2nd quarter. Millennium Management LLC now …

OncoSec Medical logoEquities research analysts expect OncoSec Medical Inc (NASDAQ:ONCS) to report earnings per share (EPS) of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for OncoSec Medical’s earnings. OncoSec Medical reported earnings per share of ($0.24) during the same quarter last year, which indicates a positive year over year growth rate of 25%. The company is expected to issue its next earnings report on Friday, March 8th.

On average, analysts expect that OncoSec Medical will report full year earnings of ($0.70) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.65). For the next financial year, analysts forecast that the firm will report earnings of ($0.84) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for OncoSec Medical.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings data on Friday, December 14th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06.

A number of research analysts recently issued reports on ONCS shares. Dawson James lowered OncoSec Medical from a “buy” rating to a “neutral” rating in a report on Wednesday, November 7th. Maxim Group set a $5.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a report on Thursday, November 29th. HC Wainwright set a $4.00 price target on shares of OncoSec Medical and gave the stock a “buy” rating in a research report on Monday, October 22nd. Finally, Piper Jaffray Companies dropped their price target on shares of OncoSec Medical from $5.00 to $3.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 6th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $4.00.

Several large investors have recently modified their holdings of ONCS. 683 Capital Management LLC acquired a new stake in OncoSec Medical in the 2nd quarter valued at $414,000. BlackRock Inc. increased its holdings in OncoSec Medical by 1,303.5% in the 2nd quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after buying an additional 221,916 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in OncoSec Medical by 19.5% in the 2nd quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock worth $1,650,000 after buying an additional 194,739 shares in the last quarter. 11.49% of the stock is currently owned by institutional investors.

ONCS traded up $0.03 during trading hours on Friday, reaching $0.72. 255,728 shares of the company’s stock traded hands, compared to its average volume of 397,861. OncoSec Medical has a 52-week low of $0.54 and a 52-week high of $2.21.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company’s investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

See Also: How mutual funds make money

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OncoSec Medical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts